Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walt Disney
DIS
|
+$207M |
| 2 |
ANSS
Ansys
ANSS
|
+$201M |
| 3 |
Woodward
WWD
|
+$192M |
| 4 |
SWN
Southwestern Energy Company
SWN
|
+$168M |
| 5 |
SQSP
Squarespace, Inc.
SQSP
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$294M |
| 2 |
Nasdaq
NDAQ
|
+$256M |
| 3 |
Salesforce
CRM
|
+$231M |
| 4 |
AstraZeneca
AZN
|
+$188M |
| 5 |
Aramark
ARMK
|
+$187M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.84% |
| 2 | Technology | 13.48% |
| 3 | Financials | 9.84% |
| 4 | Communication Services | 6.79% |
| 5 | Industrials | 6.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Zymeworks
ZYME
$2.05B
| $17.1M | 0.07% |
1,361,000
-240,000
| -15% | -$2.61M |
|
77
TAL Education Group
TAL
$6.28B
| $16.2M | 0.07% |
1,365,000
| – | – |
|
|
TECX
78
Tectonic Therapeutic
TECX
$736M
| $15.8M | 0.07% |
520,397
+89,387
| +21% | +$1.63M |
|
79
Progyny
PGNY
$1.97B
| $15.6M | 0.07% |
931,307
-377,193
| -29% | -$9.05M |
|
80
Twist Bioscience
TWST
$9.13B
| $15.4M | 0.07% |
340,650
+148,650
| +77% | +$7.07M |
|
81
Dyne Therapeutics
DYN
$4.87B
| $15.4M | 0.07% |
428,000
+422,000
| +7,033% | +$16.8M |
|
|
NUVL
82
DELISTED
Nuvalent
NUVL
| $15.3M | 0.07% |
+150,000
| New | +$12.4M |
|
83
Amgen
AMGN
$238B
| $15.1M | 0.07% |
47,000
-185,000
| -80% | -$60.5M |
|
84
Voyager Therapeutics
VYGR
$209M
| $13.4M | 0.06% |
2,292,000
| – | – |
|
85
Flutter Entertainment
FLUT
$17.8B
| $12.6M | 0.06% |
53,270
-147,530
| -73% | -$30.6M |
|
86
Biodesix
BDSX
$281M
| $8.25M | 0.04% |
231,840
+137,931
| +147% | +$4.74M |
|
|
LTM
87
LATAM Airlines Group S.A.
LTM
$14.8B
| $7.93M | 0.03% |
+300,377
| New | +$7.49M |
|
|
VTYX
88
DELISTED
Ventyx Biosciences
VTYX
| $6.91M | 0.03% |
3,170,000
| – | – |
|
89
Transmedics
TMDX
$3.29B
| $6.91M | 0.03% |
44,000
+42,000
| +2,100% | +$6.47M |
|
|
BBOT
90
BridgeBio Oncology
BBOT
$728M
| $6.27M | 0.03% |
600,000
| – | – |
|
91
AnaptysBio
ANAB
$1.71B
| $6.16M | 0.03% |
+183,876
| New | +$6.28M |
|
|
MTAL
92
DELISTED
Metals Acquisition
MTAL
| $5.68M | 0.02% |
410,197
| – | – |
|
93
Cytokinetics
CYTK
$10.7B
| $5.41M | 0.02% |
102,400
| – | – |
|
94
Amylyx Pharmaceuticals
AMLX
$4.31B
| $3.73M | 0.02% |
1,150,221
| – | – |
|
|
IVCP
95
DELISTED
Swiftmerge Acquisition Corp. Class A Ordinary Share
IVCP
| $3.31M | 0.01% |
300,000
| – | – |
|
96
Vaxcyte
PCVX
$9.32B
| $3.2M | 0.01% |
28,000
-262,000
| -90% | -$23.6M |
|
97
Prime Medicine
PRME
$615M
| $2.9M | 0.01% |
750,000
| – | – |
|
|
VNET
98
VNET Group
VNET
$1.91B
| $2.65M | 0.01% |
650,000
| – | – |
|
99
Alvotech
ALVO
$1.5B
| $2.38M | 0.01% |
+199,675
| New | +$2.32M |
|
100
Metagenomi Therapeutics
MGX
$46.5M
| $2.29M | 0.01% |
1,057,201
-286,000
| -21% | -$992K |
|
Similar funds
Thomas Steyer's Q3 2024 Portfolio in Review
As of Q3 2024, Thomas Steyer held 187 positions worth $22.8B, down 2.2% from $23.3B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Thomas Steyer withdrew a net $2.26B in Q3 2024, closing 22 positions and reducing 39 holdings. Its most notable exit was AstraZeneca, an estimated $188M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 29% a quarter earlier, followed by Technology and Financials.
Against the trend, Thomas Steyer opened a new position in Woodward worth $198M.
- Thomas Steyer's largest Q3 2024 buy was Woodward: 1,154,000 shares worth $198M.
- Thomas Steyer added most to Walt Disney in Q3 2024, an estimated $207M increase.
- Thomas Steyer's biggest Q3 2024 reduction was UnitedHealth, cutting an estimated $294M.
- Thomas Steyer fully exited AstraZeneca in Q3 2024, selling an estimated $188M.
- Thomas Steyer's ten largest holdings make up 40% of its $22.8B portfolio in Q3 2024.
- Thomas Steyer opened 21 new positions and closed 22 in Q3 2024.
- Thomas Steyer's portfolio value fell 2.2% quarter-over-quarter to $22.8B.
Based on Farallon Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.